HER2 testing in gastric and gastroesophageal junction cancers: A new therapeutic target and diagnostic challenge

Applied Immunohistochemistry and Molecular Morphology

Volumn 19, Issue 6, 2011, Pages 506-508

  Hicks, David G ^a   Whitney Miller, Christa ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

diagnosis; gastroesophageal junction cancer; HER2; immunohistochemistry; stomach cancer; trastuzumab; treatment

Indexed keywords

CAPECITABINE; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUOROURACIL; LAPATINIB; TRASTUZUMAB;

CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CANCER TISSUE; DRUG EFFICACY; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGUS RESECTION; FLUORESCENCE IN SITU HYBRIDIZATION; GASTRECTOMY; GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LOWER ESOPHAGUS SPHINCTER; MOLECULARLY TARGETED THERAPY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; STOMACH ADENOCARCINOMA; STOMACH BIOPSY; STOMACH CANCER; STOMACH CARCINOGENESIS;

ADENOCARCINOMA; ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; DIAGNOSIS, DIFFERENTIAL; ESOPHAGEAL NEOPLASMS; HUMANS; MOLECULAR TARGETED THERAPY; RECEPTOR, ERBB-2; STOMACH NEOPLASMS;

EID: 81755161341     PISSN: 15412016     EISSN: 15334058     Source Type: Journal    
DOI: 10.1097/PAI.0b013e31822c3a0f     Document Type: Review

References (10)

1. Powers DG, Kelsen DP, Shah MA. Advanced gastric cancer-slow but steady progress. Cancer Treat Rev. 2010;36:384-392.
2. Parkins DM. The global health burden of infection-associated cancers in the year 2002. Int J Cancer. 2006;118:3030-3044.
3. Hicks DG, Kulkarni S. Trastuzumab as adjuvant therapy for early breast cancer: the importance of accurate human epidermal growth factor receptor 2 testing. Arch Pathol Lab Med. 2008;132:1008-1015. (Pubitemid 351918709)
4. + breast cancer: review of biologic relevance and optimal use of diagnostic tools. Am J Clin Pathol. 2008;129:263-273. (Pubitemid 352029317)
5. Gravalos C, Jimeno A. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol. 2008;19:1523-1529.
6. Hofmann M, Stoss O, Shi D, et al. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology. 2008;52:797-805. (Pubitemid 351724903)
7. Park DI, Yun JW, Park JH, et al. HER-2/neu amplification is an independent prognostic factor in gastric cancer. Dig Dis Sci. 2006; 51:1371-1379. (Pubitemid 44315804)
8. Grabsch H, Sivakumar S, Gray S, et al. HER2 expression in gastric cancer: rare, heterogeneous and of no prognostic value-conclusions from 924 cases of two independent series. Cell Oncol. 2010;32:57-65.
9. Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomized controlled trial. Lancet. 2010;28:687-697.
10. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007;25:118-145. (Pubitemid 350003059)